scholarly journals Growth disturbances in children and adolescents receiving long‐term tyrosine kinase inhibitor therapy for Chronic Myeloid Leukaemia or Philadelphia Chromosome‐positive Acute Lymphoblastic Leukaemia

2018 ◽  
Vol 185 (4) ◽  
pp. 795-799 ◽  
Author(s):  
Himalee S. Sabnis ◽  
Caroline Keenum ◽  
Rebecca W. Lewis ◽  
Briana Patterson ◽  
John Bergsagel ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Acute Lymphoblastic Leukaemia ◽  
Tyrosine Kinase Inhibitor ◽  
Myeloid Leukaemia ◽  
Lymphoblastic Leukaemia ◽  
Kinase Inhibitor ◽  
Philadelphia Chromosome ◽  
Growth Disturbances ◽  
Tyrosine Kinase Inhibitor Therapy

Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia

2016 ◽  
Vol 91 (11) ◽  
pp. E480-E481 ◽  
Author(s):  
Simone Claudiani ◽  
Jane F. Apperley ◽  
Simona Deplano ◽  
Jamshid Khorashad ◽  
Letizia Foroni ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Myeloid Leukaemia ◽  
Cognitive Dysfunction ◽  
Kinase Inhibitor ◽  
Inhibitor Therapy ◽  
Tyrosine Kinase Inhibitor Therapy

scholarly journals GRP-011 Adherence to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia

2013 ◽  
Vol 20 (Suppl 1) ◽  
pp. A4.3-A5
Author(s):  
V González Rosa ◽  
MM Viña Romero ◽  
F Gutiérrez Nicolás ◽  
R Gavira Moreno ◽  
MT Moreno Carvajal ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Myeloid Leukaemia ◽  
Kinase Inhibitor ◽  
Inhibitor Therapy ◽  
Tyrosine Kinase Inhibitor Therapy

scholarly journals Use of Imatinib Mesylate in the Management of Chronic Myeloid Le ukaemia

2009 ◽  
Vol 22 (2) ◽  
pp. 315-318
Author(s):  
SM Kamal ◽  
MA Ahad ◽  
I Mahmood
Keyword(s):  
Cell Proliferation ◽  
Survival Rate ◽  
Chronic Myeloid Leukaemia ◽  
Acute Lymphoblastic Leukaemia ◽  
Myeloid Leukaemia ◽  
Nephrogenic Systemic Fibrosis ◽  
Kinase Inhibitor ◽  
Chromosome Abnormality ◽  
Philadelphia Chromosome ◽  
Break Point

lmatinib mesylate (Enliven) is a synthetic tyrosine kinase inhibitor. If inhibits the break point cluster region (BCR)-Abelson (ASL) fusion protein that results from the chromosome abnormality known as the Philadelphia chromosome which  leads  to  increased cell  proliferation in chronic myeloid leukaemia (CML). lmatinib is approved for the treatment of Philadelphia chromosome positive (Ph+ ) chronic myeloid leukaemia (CML). Response is good with high 5 years survival rate. It is well tolerated. lmatinib is also recommended for the treatment of Gastro­ intestinal stromal tumour (GIST), Philadelphia positive acute lymphoblastic leukaemia (ALL) and nephrogenic systemic fibrosis (NSF). Use of imatinib in CML is discussed in this review article.TAJ 2009; 22(1): 315-318

Sign in / Sign up

Export Citation Format

Share Document